Induction of Paclitaxel resistance by ERα mediated prohibitin mitochondrial-nuclear shuttling

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Dong, Pei ^a,b   Jiang, Lijuan ^a   Liu, Jianye ^a   Wu, Zhiming ^a   Guo, Shengjie ^a   Zhang, Ziling ^a   Zhou, Fangjian ^a   Liu, Zhuowei ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; PACLITAXEL; PROHIBITIN; REPRESSOR PROTEIN;

ACTIVE TRANSPORT; CELL DEATH; CELL NUCLEUS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; MITOCHONDRION; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; ESTROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MITOCHONDRIA; PACLITAXEL; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS;

EID: 84893469503     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083519     Document Type: Article

References (37)

1. Seruga B, Tannock IF (2011) Chemotherapy-based treatment for castration-resistant prostate cancer. J Clin Oncol 29: 3686-3694.
2. Rodriguez-Antona C (2010) Pharmacogenomics of paclitaxel. Pharmacogenomics 11: 621-623.
3. Doyle-Lindrud S (2012) Managing side effects of the novel taxane cabazitaxel in castrate-resistant prostate cancer. Clin J Oncol Nurs 16: 286-291.
4. Devlin HL, Mudryj M (2009) Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett 274: 177-186.
5. Powell E, Shanle E, Brinkman A, Li J, Keles S, et al. (2012) Identification of estrogen receptor dimer selective ligands reveals growth-inhibitory effects on cells that co-express ERalpha and ERbeta. PLoS One 7: e30993.
6. Carruba G (2006) Estrogens and mechanisms of prostate cancer progression. Ann N Y Acad Sci 1089: 201-217.
7. Carruba G (2007) Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario. J Cell Biochem 102: 899-911.
8. Bonkhoff H, Fixemer T, Hunsicker I, Remberger K (1999) Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. Am J Pathol 155: 641-647. (Pubitemid 29370414)
9. Prins GS, Korach KS (2008) The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids 73: 233-244.
10. Asano K, Maruyama S, Usui T, Fujimoto N (2003) Regulation of estrogen receptor alpha and beta expression by testosterone in the rat prostate gland. Endocr J 50: 281-287. (Pubitemid 36830004)
11. Barone I, Brusco L, Fuqua SA (2010) Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 16: 2702-2708.
12. Theiss AL, Sitaraman SV (2010) The role and therapeutic potential of prohibitin in disease. Biochim Biophys Acta 1813: 1137-1143.
13. Kathiria AS, Butcher LD, Feagins LA, Souza RF, Boland CR, et al. (2012) Prohibitin 1 modulates mitochondrial stress-related autophagy in human colonic epithelial cells. PLoS One 7: e31231.
14. Wang S, Nath N, Adlam M, Chellappan S (1999) Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene 18: 3501-3510. (Pubitemid 29317345)
15. Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, et al. (1997) Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 89: 601-609. (Pubitemid 27051697)
16. Gregory-Bass RC, Olatinwo M, Xu W, Matthews R, Stiles JK, et al. (2008) Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis. Int J Cancer 122: 1923-1930. (Pubitemid 351441180)
17. Patel N, Chatterjee SK, Vrbanac V, Chung I, Mu CJ, et al. (2010) Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells. Proc Natl Acad Sci U S A 107: 2503-2508.
18. Dong P, Flores J, Pelton K, Solomon KR (2010) Prohibitin is a cholesterol-sensitive regulator of cell cycle transit. J Cell Biochem 111: 1367-1374.
19. Leake RE, Habib F (1987) Steroid hormone receptors: assay and characterization.
20. Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, et al. (2008) Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J 22: 1512-1520. (Pubitemid 351656791)
21. Carruba G, Pfeffer U, Fecarotta E, Coviello DA, D'Amato E, et al. (1994) Estradiol inhibits growth of hormone-nonresponsive PC3 human prostate cancer cells. Cancer Res 54: 1190-1193. (Pubitemid 24108055)
22. Shapiro E, Huang H, Masch RJ, McFadden DE, Wilson EL, et al. (2005) Immunolocalization of estrogen receptor alpha and beta in human fetal prostate. J Urol 174: 2051-2053. (Pubitemid 41547022)
23. Lau KM, LaSpina M, Long J, Ho SM (2000) Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. Cancer Res 60: 3175-3182. (Pubitemid 30407914)
24. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, et al. (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21: 976-983. (Pubitemid 46594124)
25. Maehara Y, Emi Y, Sakaguchi Y, Kusumoto T, Kakeji Y, et al. (1990) Estrogen-receptor-negative breast cancer tissue is chemosensitive in vitro compared with estrogen-receptor-positive tissue. Eur Surg Res 22: 50-55.
26. Zhu B, Fukada K, Zhu H, Kyprianou N (2006) Prohibitin and cofilin are intracellular effectors of transforming growth factor beta signaling in human prostate cancer cells. Cancer Res 66: 8640-8647. (Pubitemid 44449179)
27. Wang S, Fusaro G, Padmanabhan J, Chellappan SP (2002) Prohibitin colocalizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression. Oncogene 21: 8388-8396. (Pubitemid 36054881)
28. Wang S, Zhang B, Faller DV (2002) Prohibitin requires Brg-1 and Brm for the repression of E2F and cell growth. EMBO J 21: 3019-3028. (Pubitemid 34670386)
29. Gamble SC, Odontiadis M, Waxman J, Westbrook JA, Dunn MJ, et al. (2004) Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene 23: 2996-3004. (Pubitemid 38648190)
30. Sripathi SR, He W, Atkinson CL, Smith JJ, Liu Z, et al. (2011) Mitochondrial-nuclear communication by prohibitin shuttling under oxidative stress. Biochemistry 50: 8342-8351.
31. Kasashima K, Ohta E, Kagawa Y, Endo H (2006) Mitochondrial functions and estrogen receptor-dependent nuclear translocation of pleiotropic human prohibitin 2. J Biol Chem 281: 36401-36410. (Pubitemid 46041374)
32. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV (2003) Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 3: 1-19. (Pubitemid 36119417)
33. Huggins C, Hodges CV (2002) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 168: 9-12.
34. Cannata DH, Kirschenbaum A, Levine AC (2012) Androgen deprivation therapy as primary treatment for prostate cancer. J Clin Endocrinol Metab 97: 360-365.
35. Harris WP, Mostaghel EA, Nelson PS, Montgomery B (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6: 76-85.
36. Small EJ, Vogelzang NJ (1997) Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 15: 382-388. (Pubitemid 27021526)
37. Montgomery B, Nelson PS, Vessella R, Kalhorn T, Hess D, et al. (2010) Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer. BMC Cancer 10: 244.